Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $40.53 million. The enterprise value is -$6.65 million.
| Market Cap | 40.53M |
| Enterprise Value | -6.65M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 31.91 million shares outstanding. The number of shares has increased by 1.22% in one year.
| Shares Outstanding | 31.91M |
| Shares Change (YoY) | +1.22% |
| Shares Change (QoQ) | +1.28% |
| Owned by Insiders (%) | 5.40% |
| Owned by Institutions (%) | 14.38% |
| Float | 29.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 16.00 |
| PS Ratio | 6.07 |
| Forward PS | 44.15 |
| PB Ratio | 0.52 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.19, with a Debt / Equity ratio of 0.04.
| Current Ratio | 10.19 |
| Quick Ratio | 9.56 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -42.40% and return on invested capital (ROIC) is -53.01%.
| Return on Equity (ROE) | -42.40% |
| Return on Assets (ROA) | -38.60% |
| Return on Capital (ROIC) | -53.01% |
| Revenue Per Employee | $43,083 |
| Profits Per Employee | -$250,900 |
| Employee Count | 155 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 1.14 |
Taxes
| Income Tax | -495,116 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.89% in the last 52 weeks. The beta is -0.83, so Co-Diagnostics's price volatility has been lower than the market average.
| Beta (5Y) | -0.83 |
| 52-Week Price Change | -15.89% |
| 50-Day Moving Average | 1.25 |
| 200-Day Moving Average | 1.21 |
| Relative Strength Index (RSI) | 48.12 |
| Average Volume (20 Days) | 92,898 |
Short Selling Information
The latest short interest is 443,619, so 1.39% of the outstanding shares have been sold short.
| Short Interest | 443,619 |
| Short Previous Month | 354,711 |
| Short % of Shares Out | 1.39% |
| Short % of Float | 1.50% |
| Short Ratio (days to cover) | 1.80 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $6.68 million and -$38.89 million in losses. Loss per share was -$1.32.
| Revenue | 6.68M |
| Gross Profit | 2.76M |
| Operating Income | -43.01M |
| Pretax Income | -39.38M |
| Net Income | -38.89M |
| EBITDA | -38.09M |
| EBIT | -39.38M |
| Loss Per Share | -$1.32 |
Balance Sheet
The company has $49.96 million in cash and $2.79 million in debt, giving a net cash position of $47.17 million or $1.48 per share.
| Cash & Cash Equivalents | 49.96M |
| Total Debt | 2.79M |
| Net Cash | 47.17M |
| Net Cash Per Share | $1.48 |
| Equity (Book Value) | 78.35M |
| Book Value Per Share | 2.46 |
| Working Capital | 48.43M |
Cash Flow
In the last 12 months, operating cash flow was -$25.07 million and capital expenditures -$1.59 million, giving a free cash flow of -$26.66 million.
| Operating Cash Flow | -25.07M |
| Capital Expenditures | -1.59M |
| Free Cash Flow | -26.66M |
| FCF Per Share | -$0.89 |
Margins
Gross margin is 41.34%, with operating and profit margins of -644.14% and -582.36%.
| Gross Margin | 41.34% |
| Operating Margin | -644.14% |
| Pretax Margin | -589.77% |
| Profit Margin | -582.36% |
| EBITDA Margin | -570.39% |
| EBIT Margin | -589.77% |
| FCF Margin | -399.23% |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.22% |
| Shareholder Yield | -1.22% |
| Earnings Yield | -95.96% |
| FCF Yield | -65.78% |
Analyst Forecast
The average price target for Co-Diagnostics is $2.00, which is 57.48% higher than the current price. The consensus rating is "Hold".
| Price Target | $2.00 |
| Price Target Difference | 57.48% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Co-Diagnostics has an Altman Z-Score of 2.1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.1 |
| Piotroski F-Score | 1 |